Vladimira Vuletić
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vladimira Vuletić has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Vida Demarin
Medical Director, Medical Centre "Aviva", Zagreb, Croatia
3 shared publicationsZeljka Lezaić
3 shared publicationsAnton Glasnović
Department of Histology and Embryology, University of Zagreb School of Medicine, Zagreb, Croatia
2 shared publicationsDanka Grčević
Department of Physiology and Immunology, and Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia
2 shared publicationsDarko Chudy
Department of Neurosurgery, University Hospital Dubrava, Zagreb, Croatia
2 shared publications- Darko Chudy
Department of Neurosurgery, Dubrava University Hospital, 10000 Zagreb, Croatia
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Publicacoes Cientificas de Acesso Aberto e Editora LTDA in Brazilian Journal of Case Reports
- Vol. 6 (1) , bjcr170
Intracerebral Hemorrhage in Multiple Sclerosis: Disease Evolution or Treatment-Related Complication?: A Case Report
Intracerebral hemorrhage (ICH) is an uncommon but clinically significant event in patients with multiple sclerosis (MS), and its relationship to disease-modifying therapies (DMTs) remains incompletely understood. We report the case of a patient with long-standing MS who developed an ICH. The patient had a 16-year history of MS and was reluctant towards long-term DMT. Cladribine was introduced as a high-efficacy treatment, and less than two years after treatment initiation, the patient experienced a spontaneous ICH. Despite the hemorrhagic event, cladribine therapy was continued, resulting in subsequent stabilization of MS disease activity, with only mild residual neurological deficit. A thorough evaluation revealed no alternative secondary causes neither conventional risk factors for the hemorrhage. Although current literature does not establish a definitive link between cladribine and ICH, the temporal relationship in this case enhances the possibility of a therapy-related contribution. Given the absence of definitive causal evidence, we propose that chronic neuroinflammation with impaired cerebrovascular autoregulation, compounded by therapy-induced immunosuppression, could contribute to the event. However, causality cannot be inferred from the single observation of disease versus treatment-related factors. Further data are needed to clarify hemorrhagic risk in MS patients receiving DMT and the need for continued pharmacovigilance when using high-efficacy immune-depleting therapies.
- 1 January 2026
- Published by Publicacoes Cientificas de Acesso Aberto e Editora LTDA in Brazilian Journal of Case Reports
- Vol. 6 (1) , bjcr170
Open AccessIntracerebral Hemorrhage in Multiple Sclerosis: Disease Evolution or Treatment-Related Complication?: A Case Report
Intracerebral hemorrhage (ICH) is an uncommon but clinically significant event in patients with multiple sclerosis (MS), and its relationship to disease-modifying therapies (DMTs) remains incompletely understood. We report the case of a patient with long-standing MS who developed an ICH. The patient had a 16-year history of MS and was reluctant towards long-term DMT. Cladribine was introduced as a high-efficacy treatment, and less than two years after treatment initiation, the patient experienced a spontaneous ICH. Despite the hemorrhagic event, cladribine therapy was continued, resulting in subsequent stabilization of MS disease activity, with only mild residual neurological deficit. A thorough evaluation revealed no alternative secondary causes neither conventional risk factors for the hemorrhage. Although current literature does not establish a definitive link between cladribine and ICH, the temporal relationship in this case enhances the possibility of a therapy-related contribution. Given the absence of definitive causal evidence, we propose that chronic neuroinflammation with impaired cerebrovascular autoregulation, compounded by therapy-induced immunosuppression, could contribute to the event. However, causality cannot be inferred from the single observation of disease versus treatment-related factors. Further data are needed to clarify hemorrhagic risk in MS patients receiving DMT and the need for continued pharmacovigilance when using high-efficacy immune-depleting therapies.
- Open Access
- 18 August 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0328761
Microbial diversity in drug-naïve Parkinson’s disease patients
Parkinson’s disease (PD) is a neurological disorder characterized by rigidity, bradykinesia and tremor. Several genetic and environmental causes of PD are known, and there is emerging evidence of the possible contribution of the gut microbiome to the disease onset, severity, and response to therapy. While previous research has shown several differences in the microbiome of PD patients under therapy as opposed to healthy controls, few prospective studies have included drug-naïve patients. In order to evaluate the gut microbiome composition prior to therapy initiation, we collected and performed 16S rRNA gene sequencing of the stool samples from 49 drug-naïve PD patients and compared them to 34 diet and lifestyle-matched controls from the Croatian population (GiOPARK Project). While no significant alpha diversity difference was observed between the patients and controls, the differential relative abundance analysis showed an increase in Bacteroides fluxus, B. interstinalis, B. eggerthii, and Dielma fastidiosa in the drug-naïve PD patients compared to controls, while Alistipes, Barnesiella and Dialister spp. were decreased in patients compared to controls. Despite preserved overall diversity, these changes may indicate early microbial dysbiosis and represent a foundation for future studies exploring microbiome changes across disease progression and treatment.
- 18 August 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0328761
Open AccessMicrobial diversity in drug-naïve Parkinson’s disease patients
Parkinson’s disease (PD) is a neurological disorder characterized by rigidity, bradykinesia and tremor. Several genetic and environmental causes of PD are known, and there is emerging evidence of the possible contribution of the gut microbiome to the disease onset, severity, and response to therapy. While previous research has shown several differences in the microbiome of PD patients under therapy as opposed to healthy controls, few prospective studies have included drug-naïve patients. In order to evaluate the gut microbiome composition prior to therapy initiation, we collected and performed 16S rRNA gene sequencing of the stool samples from 49 drug-naïve PD patients and compared them to 34 diet and lifestyle-matched controls from the Croatian population (GiOPARK Project). While no significant alpha diversity difference was observed between the patients and controls, the differential relative abundance analysis showed an increase in Bacteroides fluxus, B. interstinalis, B. eggerthii, and Dielma fastidiosa in the drug-naïve PD patients compared to controls, while Alistipes, Barnesiella and Dialister spp. were decreased in patients compared to controls. Despite preserved overall diversity, these changes may indicate early microbial dysbiosis and represent a foundation for future studies exploring microbiome changes across disease progression and treatment.
- Open Access
- 29 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3811
The Role of Preoperative Immunonutritional Scores in Predicting Complications After Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder associated with systemic inflammation, immune dysregulation, and malnutrition, all of which may influence surgical outcomes. Subthalamic nucleus deep brain stimulation (STN DBS) is a widely used treatment for advanced PD, yet postoperative complications remain a concern. This study evaluates the predictive value of preoperative immunonutritional markers—including the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score, Aggregate Index of Systemic Inflammation (AISI), Lymphocyte-to-Monocyte Ratio (LMR), and systemic inflammatory response syndrome (SIRS)—for the risk of extracranial complications following STN DBS. Methods: A retrospective cohort study was conducted on 138 PD patients who underwent STN DBS. Clinical and laboratory data were analyzed to assess the association between preoperative immunonutritional markers and postoperative complications, including infections, wound healing disturbances, and surgical revisions. Logistic regression and receiver operating characteristic (ROC) analysis were performed to evaluate the predictive power of these markers. Results: SIRS emerged as the strongest predictor of complications (aOR = 6.99, 95% CI = 1.844–26.509), emphasizing the critical role of systemic inflammation in surgical outcomes. HALP, AISI, and LMR also demonstrated significant predictive potential, with HALP (AUC = 0.69) and LMR (AUC = 0.73) being the most robust predictors of complications. While albumin alone was not a significant predictor, it correlated with inflammatory markers and comorbidities, underscoring its role in broader risk assessments. Conclusions: This study underscores the value of preoperative immunonutritional markers in predicting complications following STN DBS in PD patients. Incorporating these markers into clinical risk stratification may enhance preoperative planning and personalized postoperative care, ultimately improving surgical outcomes. These findings, while promising, warrant validation through prospective, multicenter studies to refine predictive models and enhance patient outcomes.
- 29 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3811
Open AccessThe Role of Preoperative Immunonutritional Scores in Predicting Complications After Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder associated with systemic inflammation, immune dysregulation, and malnutrition, all of which may influence surgical outcomes. Subthalamic nucleus deep brain stimulation (STN DBS) is a widely used treatment for advanced PD, yet postoperative complications remain a concern. This study evaluates the predictive value of preoperative immunonutritional markers—including the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score, Aggregate Index of Systemic Inflammation (AISI), Lymphocyte-to-Monocyte Ratio (LMR), and systemic inflammatory response syndrome (SIRS)—for the risk of extracranial complications following STN DBS. Methods: A retrospective cohort study was conducted on 138 PD patients who underwent STN DBS. Clinical and laboratory data were analyzed to assess the association between preoperative immunonutritional markers and postoperative complications, including infections, wound healing disturbances, and surgical revisions. Logistic regression and receiver operating characteristic (ROC) analysis were performed to evaluate the predictive power of these markers. Results: SIRS emerged as the strongest predictor of complications (aOR = 6.99, 95% CI = 1.844–26.509), emphasizing the critical role of systemic inflammation in surgical outcomes. HALP, AISI, and LMR also demonstrated significant predictive potential, with HALP (AUC = 0.69) and LMR (AUC = 0.73) being the most robust predictors of complications. While albumin alone was not a significant predictor, it correlated with inflammatory markers and comorbidities, underscoring its role in broader risk assessments. Conclusions: This study underscores the value of preoperative immunonutritional markers in predicting complications following STN DBS in PD patients. Incorporating these markers into clinical risk stratification may enhance preoperative planning and personalized postoperative care, ultimately improving surgical outcomes. These findings, while promising, warrant validation through prospective, multicenter studies to refine predictive models and enhance patient outcomes.
- Open Access
- 30 September 2020
- Published by IntechOpen
Deep Brain Stimulation in Non-motor Symptoms of Neurodegenerative Diseases
Deep brain stimulation (DBS) is a functional neuromodulatory technique that involves the use of a neurostimulator to deliver electrical impulses to the brain. It primarily alleviates the motor symptoms in neurodegenerative diseases; however, it has been found beneficial in a multitude of neurological and psychiatric diseases, such as dystonia, essential tremor, Tourette syndrome, intractable pain, epilepsy, treatment-resistant depression, and obsessive-compulsive disorder. Nonmotor symptoms, such as neurobehavioral disorders, autonomic dysfunction, sleep dysfunction, and somatosensory dysfunction, play an important role in neurodegenerative diseases and have a significant impact on the quality of life. The effects of deep brain stimulation on these symptoms are not yet apparent, although early results are promising and warrant future investigations. The main problem in interpretation is the lack of studies in this field, as most have methodological issues or small sample sizes, which limit the strength of the evidence. However, it is clear that DBS has a promising future in the treatment of neurodegenerative diseases in general and will have a vital role in personalized medicine as functional neuroimaging and our understanding of brain physiology improve.
- 30 September 2020
- Published by IntechOpen
Open AccessDeep Brain Stimulation in Non-motor Symptoms of Neurodegenerative Diseases
Deep brain stimulation (DBS) is a functional neuromodulatory technique that involves the use of a neurostimulator to deliver electrical impulses to the brain. It primarily alleviates the motor symptoms in neurodegenerative diseases; however, it has been found beneficial in a multitude of neurological and psychiatric diseases, such as dystonia, essential tremor, Tourette syndrome, intractable pain, epilepsy, treatment-resistant depression, and obsessive-compulsive disorder. Nonmotor symptoms, such as neurobehavioral disorders, autonomic dysfunction, sleep dysfunction, and somatosensory dysfunction, play an important role in neurodegenerative diseases and have a significant impact on the quality of life. The effects of deep brain stimulation on these symptoms are not yet apparent, although early results are promising and warrant future investigations. The main problem in interpretation is the lack of studies in this field, as most have methodological issues or small sample sizes, which limit the strength of the evidence. However, it is clear that DBS has a promising future in the treatment of neurodegenerative diseases in general and will have a vital role in personalized medicine as functional neuroimaging and our understanding of brain physiology improve.
- 19 June 2018
- Published by S. Karger AG in Neuroimmunomodulation
- Vol. 25 (1) , 23-33
RANKL/RANK/OPG Axis Is Deregulated in the Cerebrospinal Fluid of Multiple Sclerosis Patients at Clinical Onset
Objectives: Our study focused on the RANKL (receptor activator of nuclear factor-κB ligand)/RANK/OPG (osteoprotegerin) axis and selected proinflammatory/immunoregulatory upstream mediators in the peripheral blood (PBL) and cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients. Methods: PBL and CSF were collected from healthy controls (n = 35) and MS patients at the clinical onset of the disease (n = 33). In addition, PBL samples were obtained from relapse-remitting (RR)-MS patients (n = 30). Patients were assessed by means of the expanded disability status scale (EDSS) and routine laboratory parameters. Soluble (s)RANKL and OPG were measured in the CSF and plasma; gene expression was detected for RANKL, RANK, OPG, and selected cytokines/chemokines (interleukin [IL]-4, IL-10, IL-17, CCL2, and CXCL12) in PBL mononuclear cells. Results: The OPG level in the CSF was lower in MS patients at clinical onset than in controls. Moreover, the sRANKL/OPG ratio was higher in the CSF of MS patients at clinical onset and in the plasma of RR-MS patients than in controls. Gene expression of RANKL/RANK/OPG in PBL mononuclear cells was higher only in RR-MS patients. IL-4, CCL2, and CXCL12 were positively correlated and IL-10 was negatively correlated with RANKL/RANK expression. OPG was negatively correlated with EDSS and alkaline phosphatase level. Conclusion: Our study revealed that changes of RANKL/RANK/OPG axis are associated with MS, particularly the decreased OPG level in the CSF at disease onset. Therefore, these factors may serve as disease biomarkers and molecular targets of novel therapeutic approaches.
- 19 June 2018
- Published by S. Karger AG in Neuroimmunomodulation
- Vol. 25 (1) , 23-33
RANKL/RANK/OPG Axis Is Deregulated in the Cerebrospinal Fluid of Multiple Sclerosis Patients at Clinical Onset
Objectives: Our study focused on the RANKL (receptor activator of nuclear factor-κB ligand)/RANK/OPG (osteoprotegerin) axis and selected proinflammatory/immunoregulatory upstream mediators in the peripheral blood (PBL) and cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients. Methods: PBL and CSF were collected from healthy controls (n = 35) and MS patients at the clinical onset of the disease (n = 33). In addition, PBL samples were obtained from relapse-remitting (RR)-MS patients (n = 30). Patients were assessed by means of the expanded disability status scale (EDSS) and routine laboratory parameters. Soluble (s)RANKL and OPG were measured in the CSF and plasma; gene expression was detected for RANKL, RANK, OPG, and selected cytokines/chemokines (interleukin [IL]-4, IL-10, IL-17, CCL2, and CXCL12) in PBL mononuclear cells. Results: The OPG level in the CSF was lower in MS patients at clinical onset than in controls. Moreover, the sRANKL/OPG ratio was higher in the CSF of MS patients at clinical onset and in the plasma of RR-MS patients than in controls. Gene expression of RANKL/RANK/OPG in PBL mononuclear cells was higher only in RR-MS patients. IL-4, CCL2, and CXCL12 were positively correlated and IL-10 was negatively correlated with RANKL/RANK expression. OPG was negatively correlated with EDSS and alkaline phosphatase level. Conclusion: Our study revealed that changes of RANKL/RANK/OPG axis are associated with MS, particularly the decreased OPG level in the CSF at disease onset. Therefore, these factors may serve as disease biomarkers and molecular targets of novel therapeutic approaches.
- 1 June 2018
- Published by University of Rijeka, Faculty of Medicine in Medicina Fluminensis
- Vol. 54 (2) , 140-154
Diagnostic and therapeutic approach to a patient with cognitive impairment
Dementia is a clinical syndrome which manifests in a decline in one or more cognitive domains (learning, memory, language, egsecutive function, attention, perceptive, motor and social cognition) that affects patients rutine daily...
- 1 June 2018
- Published by University of Rijeka, Faculty of Medicine in Medicina Fluminensis
- Vol. 54 (2) , 140-154
Diagnostic and therapeutic approach to a patient with cognitive impairment
Dementia is a clinical syndrome which manifests in a decline in one or more cognitive domains (learning, memory, language, egsecutive function, attention, perceptive, motor and social cognition) that affects patients rutine daily...
- 31 October 2017
- Published by Springer Nature in Journal of Biological Physics
- Vol. 44 (1) , 53-80
Calcium–axonemal microtubuli interactions underlie mechanism(s) of primary cilia morphological changes
We have used cell culture of astrocytes aligned within microchannels to investigate calcium effects on primary cilia morphology. In the absence of calcium and in the presence of flow of media (10 μL.s−1) the majority (90%) of primary cilia showed reversible bending with an average curvature of 2.1 ± 0.9 × 10−4 nm−1. When 1.0 mM calcium was present, 90% of cilia underwent bending. Forty percent of these cilia demonstrated strong irreversible bending, resulting in a final average curvature of 3.9 ± 1 × 10−4 nm−1, while 50% of cilia underwent bending similar to that observed during calcium-free flow. The average length of cilia was shifted toward shorter values (3.67 ± 0.34 μm) when exposed to excess calcium (1.0 mM), compared to media devoid of calcium (3.96 ± 0.26 μm). The number of primary cilia that became curved after calcium application was reduced when the cell culture was pre-incubated with 15 μM of the microtubule stabilizer, taxol, for 60 min prior to calcium application. Calcium caused single microtubules to curve at a concentration ≈1.0 mM in vitro, but at higher concentration (≈1.5 mM) multiple microtubule curving occurred. Additionally, calcium causes microtubule-associated protein-2 conformational changes and its dislocation from the microtubule wall at the location of microtubule curvature. A very small amount of calcium, that is 1.45 × 1011 times lower than the maximal capacity of TRPPs calcium channels, may cause gross morphological changes (curving) of primary cilia, while global cytosol calcium levels are expected to remain unchanged. These findings reflect the non-linear manner in which primary cilia may respond to calcium signaling, which in turn may influence the course of development of ciliopathies and cancer.
- 31 October 2017
- Published by Springer Nature in Journal of Biological Physics
- Vol. 44 (1) , 53-80
Calcium–axonemal microtubuli interactions underlie mechanism(s) of primary cilia morphological changes
We have used cell culture of astrocytes aligned within microchannels to investigate calcium effects on primary cilia morphology. In the absence of calcium and in the presence of flow of media (10 μL.s−1) the majority (90%) of primary cilia showed reversible bending with an average curvature of 2.1 ± 0.9 × 10−4 nm−1. When 1.0 mM calcium was present, 90% of cilia underwent bending. Forty percent of these cilia demonstrated strong irreversible bending, resulting in a final average curvature of 3.9 ± 1 × 10−4 nm−1, while 50% of cilia underwent bending similar to that observed during calcium-free flow. The average length of cilia was shifted toward shorter values (3.67 ± 0.34 μm) when exposed to excess calcium (1.0 mM), compared to media devoid of calcium (3.96 ± 0.26 μm). The number of primary cilia that became curved after calcium application was reduced when the cell culture was pre-incubated with 15 μM of the microtubule stabilizer, taxol, for 60 min prior to calcium application. Calcium caused single microtubules to curve at a concentration ≈1.0 mM in vitro, but at higher concentration (≈1.5 mM) multiple microtubule curving occurred. Additionally, calcium causes microtubule-associated protein-2 conformational changes and its dislocation from the microtubule wall at the location of microtubule curvature. A very small amount of calcium, that is 1.45 × 1011 times lower than the maximal capacity of TRPPs calcium channels, may cause gross morphological changes (curving) of primary cilia, while global cytosol calcium levels are expected to remain unchanged. These findings reflect the non-linear manner in which primary cilia may respond to calcium signaling, which in turn may influence the course of development of ciliopathies and cancer.
- 18 April 2016
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 366, 18-19
Excellent outcome of pallidal deep brain stimulation in DYT6 dystonia: A case report
- 18 April 2016
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 366, 18-19
Excellent outcome of pallidal deep brain stimulation in DYT6 dystonia: A case report
- 1 February 2016
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 361, 7-8
Thrombolysis for acute stroke in patient with systemic lupus erythematosus: A case report
- 1 February 2016
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 361, 7-8
Thrombolysis for acute stroke in patient with systemic lupus erythematosus: A case report